Gene · 2073
Papers2,901
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 2,901
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CrypticProteinDB: an integrated database of proteome and immunopeptidome derived non-canonical cancer proteins. | NAR Cancer | 2023 | 37275273 | PubTator, text mining | PubMed |
| Brain Calcifications: Genetic, Molecular, and Clinical Aspects. | Int J Mol Sci | 2023 | 37240341 | PubTator, text mining | PubMed |
| DNA Repair Pathway in Ovarian Cancer Patients Treated with HIPEC. | Int J Mol Sci | 2023 | 37240218 | PubTator, text mining | PubMed |
| The FBXO32/ATR/ATM axis acts as a molecular switch to control the sensitivity of osteosarcoma cells to irradiation through its regulation of EXO1 expression. | Acta Biochim Biophys Sin (Shanghai) | 2023 | 37227155 | PubTator, text mining | PubMed |
| Genetic variability of oxidative stress and DNA repair genes associated with pre-treatment cancer-related fatigue in women with breast cancer. | Support Care Cancer | 2023 | 37212918 | PubTator, text mining | PubMed |
| High expression of transcription factor POU2F1 confers improved survival on smokers with lung adenocarcinoma: a retrospective study of two cohorts. | Transl Lung Cancer Res | 2023 | 37197633 | PubTator, text mining | PubMed |
| Screening and Identification of a Prognostic Model of Ovarian Cancer by Combination of Transcriptomic and Proteomic Data. | Biomolecules | 2023 | 37189432 | PubTator, text mining | PubMed |
| Molecular mechanisms protecting centromeres from self-sabotage and implications for cancer therapy. | NAR Cancer | 2023 | 37180029 | PubTator, text mining | PubMed |
| Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications. | Signal Transduct Target Ther | 2023 | 37179402 | PubTator, text mining | PubMed |
| Dynamic conformational switching underlies TFIIH function in transcription and DNA repair and impacts genetic diseases. | Nat Commun | 2023 | 37179334 | PubTator, text mining | PubMed |
| Diverse genetic spectrum among patients who met the criteria of hereditary breast, ovarian and pancreatic cancer syndrome. | J Gynecol Oncol | 2023 | 37170728 | PubTator, text mining | PubMed |
| Nucleotide excision repair in Human cell lines lacking both XPC and CSB proteins. | Nucleic Acids Res | 2023 | 37144462 | PubTator, text mining | PubMed |
| Genomic mutation landscape of skin cancers from DNA repair-deficient xeroderma pigmentosum patients. | Nat Commun | 2023 | 37142601 | PubTator, text mining | PubMed |
| Whole Exome Sequencing of a Patient with a Milder Phenotype of Xeroderma Pigmentosum Group C. | Medicina (Kaunas) | 2023 | 37109656 | PubTator, text mining | PubMed |
| Cisplatin in Ovarian Cancer Treatment-Known Limitations in Therapy Force New Solutions. | Int J Mol Sci | 2023 | 37108749 | PubTator, text mining | PubMed |
| The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers. | Int J Mol Sci | 2023 | 37108451 | PubTator, text mining | PubMed |
| Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non-small cell lung cancer: A large real-world cohort and review of the literature. | Thorac Cancer | 2023 | 37095004 | PubTator, text mining | PubMed |
| Exo1 protects DNA nicks from ligation to promote crossover formation during meiosis. | PLoS Biol | 2023 | 37079643 | PubTator, text mining | PubMed |
| Lesion recognition by XPC, TFIIH and XPA in DNA excision repair. | Nature | 2023 | 37076618 | PubTator, text mining | PubMed |
| Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial. | Blood Adv | 2023 | 37058477 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2073/papers?page=10